Volition Signs First Human Out-Licensing Deal for Nu.Q NETs Test with Werfen's Immunoassay Technology Center for Antiphospholipid Syndrome

VolitionRx Limited has signed a research license and exclusive commercial option rights agreement with Werfen for the use of Volition's Nu.Q NETs test in diagnosing Antiphospholipid Syndrome (APS). The deal grants Werfen access to Volition's proprietary assay and the option to launch the product commercially under an exclusive license. Werfen will investigate the clinical utility of the test in APS patients and has already successfully transferred the Nu.Q NETs assay to its ACL AcuStar platform.